Cellular Biomedicine Group (NASDAQ:CBMG) Upgraded by BidaskClub to Hold

0
26
Savings, Finance, Currency, Piggy Bank, Wages

Cellular Biomedicine Group stock has undergone multiple analysts rating changes in the recent past.  Cellular Biomedicine Group Upgraded by BidaskClub on 6/30/2020. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

Shares of Cellular Biomedicine Group traded down -$1.08 on Monday, reaching $14.89. 0 shares of the stock traded hands, compared to its average volume of 84704. Shares of Cellular Biomedicine Group ended Monday on at $14.89. The firm’s 50 day moving average is $14.03 and its 200 day moving average is $15.65.Cellular Biomedicine Group  has a 12 month low of $14.52 and a 12 month high of $18.99. While on yearly highs and lows, Cellular Biomedicine Group’s today has traded high as $16.29 and has touched $14.52 on the downward trend. See More Analyst Rating at: RATING

Cellular Biomedicine Group Earnings and What to expect: 

Cellular Biomedicine Group last released its quarterly earnings data on May 6th, 2020. The biotechnology company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.18. Cellular Biomedicine Group has generated ($2.63) earnings per share over the last year. Cellular Biomedicine Group has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, August 4th, 2020 based off prior year’s report dates.

Earnings for Cellular Biomedicine Group are expected to decrease in the coming year, from ($2.96) to ($2.97) per share. The P/E ratio of Cellular Biomedicine Group is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Cellular Biomedicine Group is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Cellular Biomedicine Group has a P/B Ratio of 5.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 8.50%
  • On 4/10/2018 Director Wen Tao Liu Sell 10,400 at average share price of $20.10 which equates to $209,040.00 in money value.
  • On 12/22/2017 SVP Andrew K. Chan Buy 8,333 at average price of  $12.00 with total value of : Not Data Available
  • On 12/22/2017 CEO Tony Liu Buy 29,167 at average price of  $12.00 with total value of : $350,004.00

Analyst at BidaskClub are also talking about :

  • 6/30/2020 – Winmark was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/30/2020 – Vaxart was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/30/2020 – VSE was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/30/2020 – Verisign was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

Cellular Biomedicine Group (NASDAQ:CBMG) Moving Average Technical Analysis

5 day Moving Average is $15.46 And 5 day price change is $0.45 (3.12%)  with average volume for 5 day average is 97,200. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $13.60 and 20 day price change is $1.76 (13.40%) and average 20 day moving volume is 82,035. 50 day moving average is $14.03  and 50 day price change is -$0.67 ( -4.31%)  and with average volume for 50 days is : 84,818. 200 day moving average is $15.65  and 200 day price change is $0.37 (2.55%)  and with average volume for 200 days is : 61,283.

See More Analyst Rating at: RATING